In 2020, the European Medicines Agency (EMA) (https://www.ema.europa.eu/en/documents/variation‐report/keytruda‐h‐c‐3820‐ii‐0065‐epar‐assessment‐report‐variation_en.pdf) and the UK’s National Institute for Health and Care Excellence (NICE), with their guideline documents, approved pembrolizumab, both as monotherapy and in combination with chemotherapy, as a first‐line treatment for metastatic or unresectable recurrent HNSCC in patients whose tumours express PD‐L1 with CPS ≥ 1, regardless of the test (antibody and IHC platform) used.12, 13. This evidence concerns the gene CD274 and neoplasm.